Blocking which ion channel current is the primary mechanism of Class III antiarrhythmic drugs?
Choose an answer, then check it.
Clinical Pharmacology · Antiarrhythmic Medications
Potassium Channel Blockers
On this page 6 sections
In 30 seconds
Class III antiarrhythmics block potassium channels that normally repolarize the heart, prolonging the cardiac action potential and refractory period. This suppresses reentrant arrhythmias but carries a shared hazard: a longer QT interval and the risk of torsades de pointes. Amiodarone dominates this class — extraordinarily effective and extraordinarily promiscuous in its toxicity — while sotalol, dofetilide, dronedarone, and ibutilide fill narrower, tightly monitored roles.
The college version
The mechanism behind Class III
Cardiac cells depolarize via a fast sodium influx and repolarize as potassium exits the cell. Class III drugs block the potassium channels responsible for that repolarizing current. Slowing repolarization lengthens the action potential and the effective refractory period — the window during which a cell cannot be prematurely re-excited. A longer refractory period makes it harder for a reentrant electrical loop to sustain itself, so these drugs work against atrial and ventricular tachyarrhythmias alike. The same prolongation shows up on the ECG as a longer QT interval, and an excessively long QT sets up torsades de pointes, a polymorphic ventricular tachycardia. Every drug in this class carries that tradeoff.
Amiodarone: the workhorse with baggage
Amiodarone is used far more than any other Class III agent, for atrial fibrillation and for life-threatening ventricular arrhythmias, including during cardiac arrest resuscitation. Its defining feature is that it is not a pure Class III drug — it also blocks sodium channels, beta-adrenergic receptors, and calcium channels, making it a genuinely multi-class agent unusually effective across arrhythmia types. Pharmacokinetically it is unlike almost anything else in cardiology: an enormous volume of distribution because it is highly lipophilic and accumulates in fat, liver, and lung, and a half-life measured in weeks. Effects build slowly, persist long after the drug is stopped, and interactions can linger.
Amiodarone's toxicity touches nearly every organ system, so baseline and periodic monitoring is standard practice. The lungs risk pulmonary fibrosis, an insidious, potentially irreversible complication warranting baseline and follow-up pulmonary assessment. The thyroid is affected because each molecule carries substantial iodine, and the drug can cause either hypothyroidism or hyperthyroidism, so thyroid function is checked before starting and periodically after. The liver can develop hepatotoxicity, so liver enzymes are monitored. The eyes commonly develop corneal microdeposits, usually inconsequential, though a rarer optic neuropathy can threaten vision. The skin can develop a striking blue-gray discoloration with long-term use and marked photosensitivity. Neurologic effects such as tremor, ataxia, and peripheral neuropathy can also occur.
Amiodarone is also a major interaction hazard because it inhibits multiple drug-metabolizing pathways: it potentiates warfarin, raising bleeding risk and typically requiring a lower anticoagulant dose with closer monitoring; it raises digoxin levels, risking toxicity; and it raises statin levels, increasing myopathy risk. Starting or stopping amiodarone should prompt a review of the whole medication regimen.
The other Class III agents
Dronedarone is a chemical relative of amiodarone engineered to reduce iodine-related thyroid and lung toxicity, but it is meaningfully less effective and is contraindicated in decompensated heart failure and in permanent atrial fibrillation, since trials showed increased mortality in those populations.
Sotalol combines nonselective beta-blockade with potassium channel blockade, giving it both Class II and Class III activity. Because its QT-prolonging effect can provoke torsades early in treatment, initiation happens in an inpatient setting with continuous ECG and QT monitoring. Since it is renally eliminated, its dose must be adjusted for reduced kidney function to avoid accumulation and excessive QT prolongation.
Dofetilide is a more selective potassium channel blocker used mainly for atrial fibrillation and flutter. It requires strict, protocol-driven inpatient initiation with ECG monitoring, renal function assessment, and electrolyte correction before and during loading, reflecting a narrow margin between benefit and torsades risk.
Ibutilide is used for acute pharmacologic conversion of atrial fibrillation or flutter, given as a monitored intravenous infusion with continuous ECG observation during and after dosing, since torsades risk peaks in the hours right after administration.
Shared safety themes
Because every Class III drug prolongs the QT interval, several practices recur across the class: baseline and follow-up ECG monitoring, avoiding other QT-prolonging medications, and correcting low potassium and low magnesium before and during therapy, since both disturbances independently prolong the QT interval and lower the torsades threshold. If torsades develops, intravenous magnesium is first-line treatment regardless of the patient's measured magnesium level, because it stabilizes the myocardial membrane and suppresses triggering activity even when magnesium stores are technically normal.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Think of your heart's electrical system like a light switch that has to fully reset before it can flip again. Potassium is what resets it. These medicines slow down that reset button on purpose, so the switch takes longer before it's ready to flip. That's good because it stops the heart from firing extra, chaotic signals. But if the reset takes too long, sometimes the switch misfires in a dangerous, wobbly way instead — that's the risky rhythm called torsades.
Amiodarone is the big, powerful tool in this toolbox. It doesn't just slow the reset button — it fiddles with almost every part of the heart's wiring at once, which is why it works so well. But it sticks around in the body for a long time, like glitter that never vacuums fully out of a carpet, and it can quietly bother other body parts too: lungs, thyroid, liver, eyes, and skin, which can turn grayish-blue with long use. That's why doctors check on all those things regularly with blood tests, breathing tests, and eye exams. The other medicines in this family are more focused tools with strict rules, like staying in the hospital hooked to a heart monitor when starting, because the same slow-reset trick can misfire if unwatched.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient started on sotalol develops a markedly prolonged QT interval on telemetry during hospital initiation. Which two electrolytes should be checked and corrected?
Show answer
Potassium and magnesium.
Low potassium and low magnesium both lengthen the QT interval and make torsades more likely, so correcting both helps protect the patient while sotalol's rhythm effect is being watched.
A patient on stable warfarin therapy starts amiodarone for recurrent atrial fibrillation. What change should be anticipated in the warfarin regimen and why?
Show answer
The warfarin dose is typically reduced and monitored more closely.
Amiodarone slows how the body clears warfarin, so without adjustment the same warfarin dose would build up and raise bleeding risk once amiodarone is added.
Quick check
3 questions here. Answers stay hidden until you check.
Which monitoring concern is most specifically tied to amiodarone's iodine content?
Choose an answer, then check it.
Which statement about dronedarone is accurate?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.